Interestingly, in breast cancer patient samples, YKT6 was upregulated in p53-mutated tumors that were resistant to docetaxel, while the in vitro silencing of YKT6 in breast cancer cells enhanced docetaxel-induced apoptosis [16]. Here, TP53 is linked to breast carcinoma.